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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: This retrospective database analysis compared the effectiveness of dihydropyridine 
calcium channel blockers (DHPs), angiotensin-converting enzyme (ACE) inhibitors, and angio-
tensin receptor blockers (ARBs) added to diuretics or β-blockers. Adults with hypertension 
treated with diuretic or β-blocker monotherapy between 1998 and 2001 were identiﬁ  ed from a 
large US electronic medical records database of primary care practices. Patients were required 
to have a baseline blood pressure (BP) 140/90 mmHg (130/80 mmHg for diabetes mellitus) 
and recorded BP measurements within 6 months before and 1–12 months following index date. 
Patients were matched 1:1:1 by propensity score to correct for differences in baseline charac-
teristics. 1875 patients met study criteria and 660 (220 in each cohort) were matched based on 
propensity scores. Matched cohorts had no signiﬁ  cant differences in baseline characteristics. 
Mean changes in systolic/diastolic BP were –17.5/–8.8, –15.7/–6.3, and –13.0/–8.0 mmHg with 
DHPs, ACE inhibitors, and ARBs, respectively. Joint National Committee on the Prevention, 
Detection, Evaluation, and Treatment of High BP 6/7 goal attainment for each regimen was 
47.3%, 40.0%, and 32.2%, respectively. DHPs, ACE inhibitors, and ARBs improved BP when 
added to patients’ β-blocker or diuretic therapy. The greatest beneﬁ  ts were observed with DHPs, 
followed by ACE inhibitors, then ARBs.
Keywords: hypertension, amlodipine besylate, lisinopril, valsartan, Joint National Committee 
(JNC) 6 and 7
Introduction
Hypertension is a key independent risk factor for cardiovascular diseases (CVD), such 
as heart failure, stroke, coronary heart disease (CHD), and end-stage renal disease 
(Chobanian et al 2003).
Morbidity and mortality from hypertension-associated disease have been reduced 
in the US over the past three decades (Chobanian et al 2003). However, past progress 
has not been maintained. The prevalence of hypertension in the US has increased 
recently (Hajjar and Kotchen 2003). Death rates from CHD and stroke have failed to 
further improve, and end-stage renal disease is being diagnosed at increasing rates 
(Chobanian et al 2003). Importantly, more than two thirds of hypertensive adults in 
the US do not have their BP under control, manifesting BP levels 140/90 mmHg 
(Chobanian et al 2003; Hajjar and Kotchen 2003).
The Sixth Report of the Joint National Committee (JNC) on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 6) recommended initiation 
of antihypertensive therapy using a diuretic or β-blocker for patients who have no 
speciﬁ  c indications for other drug classes (Joint National Committee 1997). The sub-Vascular Health and Risk Management 2006:2(4) 465–475
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sequent JNC 7 guidelines recommended thiazide diuretics as 
the preferred initial agent (Chobanian et al 2003). However, 
approximately half of patients treated for hypertension do not 
respond to monotherapy (Materson et al 1993). Indeed, large 
landmark clinical trials have shown that patients often require 
up to four medications to achieve BP control (Hansson et al 
1998; ALLHAT Collaborative Research Group 2002; Dahlöf 
et al 2002; Black et al 2003). It is now accepted that in order 
to achieve BP goals, most patients will require at least two 
antihypertensive agents, each from a different class, includ-
ing diuretics, β-blockers, angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARBs), and 
dihydropyridine calcium channel blockers (DHPs) (Bakris 
2001; American Diabetes Association 2002; Chobanian et al 
2003; Guidelines Committee 2003).
Despite support for the use of multiple therapies in treat-
ing hypertension, few studies have compared the effective-
ness of different antihypertensive classes and agents as part 
of a multidrug regimen in real-world clinical practice. Many 
real-world issues, such as suboptimal patient adherence with 
medications, are often not accounted for in clinical trials 
(Monane et al 1997; Burnier et al 2001). The objective of this 
retrospective cohort analysis was to compare, within a physi-
cian ofﬁ  ce setting, the clinical effectiveness of DHPs, ACE 
inhibitors, and ARBs when added to diuretic or β-blocker 
therapy in patients who had previously received a diuretic 
or β-blocker, but had failed to achieve their BP goal. This 
study compared the effectiveness of different multiple anti-
hypertensive regimens used in a way that mirrored the JNC 
6 treatment recommendations that were in effect during the 
time period of the study cohort. Clinical effectiveness was 
measured by absolute BP reductions as well as by attainment 
of BP goals speciﬁ  ed by key treatment guidelines, including 
both JNC 6 and 7.
Methods
Data source
This retrospective database analysis used encrypted data 
extracted from the GE Medical Quality Improvement Con-
sortium Electronic Medical Records (EMR) database. At 
the time of this analysis, the database contained longitudinal 
data for approximately 370,000 patients who were receiving 
treatment from primary care physicians across the US. Data 
collected from patient records included demographics and 
diagnoses, prescribed medications and procedures, cardiac 
risk factors, test results, and patient functional status. Physi-
cians were from large practices in Oregon, Arizona, Texas, 
Massachusetts, Iowa, Virginia, New Hampshire, and Maine 
who had been using the EMR database for at least 1 year at 
study initiation.
Study population
Patients aged 20 years who visited a physician’s ofﬁ  ce dur-
ing a 4-year period (1998 through 2001), had a documented 
diagnosis of hypertension (ICD-9-CM: 401.xx) and/or 
“hypertension/high BP” documented in the problem list, and 
initiated add-on treatment with any ACE inhibitor, ARB, 
or DHP were identiﬁ  ed for the study. Add-on therapy was 
operationally deﬁ  ned as patients already receiving β-blocker 
or diuretic therapy at the time the ACE, ARB, or DHP was 
initiated; therefore, all study patients were required to be 
receiving prior treatment with a β-blocker or diuretic. Those 
patients receiving ACE inhibitor/diuretic or ARB/diuretic 
ﬁ  xed-dose combinations were included only if they previ-
ously used a diuretic and had discontinued the diuretic at the 
time the ﬁ  xed-dose combination was initiated.
At least two valid BP readings (pre- and post-index) were 
required for each patient. The pre-index (or baseline) BP 
reading, deﬁ  ned as the most recent measurement within 6 
months before the initiation of ACE inhibitor, ARB, or DHP 
therapy, was required to be 140/90 mmHg for patients who 
did not have diabetes and 130/80 mmHg for patients with 
diabetes mellitus. The post-index measurement was the ﬁ  nal 
BP reading between 1 to 12 months following the index date 
and must have been taken before the earliest of the following 
events: discontinuation of the ACE inhibitor, ARB, or DHP; 
initiation of any other antihypertensive agent; or 12 months 
after initiation of the ACE inhibitor, ARB, or DHP. Con-
sequently, patients who initiated another antihypertensive 
agent on the same day or within the ﬁ  rst month of initiating 
the index ACE inhibitor, ARB, or DHP were excluded, as 
were patients who discontinued their index product within 
1 month of its initiation. Patients also were excluded if they 
had a recorded diagnosis of congestive heart failure or pre-
vious treatment with any other antihypertensive agent. The 
time frame for the study is depicted in Figure 1.
Data collection
Patient demographics at baseline included age, sex, and 
weight. During the study period, a number of data were 
collected to enable comparison of disease severity between 
patient groups. These data included patients’ age, comorbid 
hyperlipidemia, diabetes, coronary artery disease and/or, 
end-stage renal disease, baseline SBP and DBP, and JNC 
6 BP stage, the number of BP measurements during the 6 
months prior to ACE inhibitor, ARB, or DHP initiation, Vascular Health and Risk Management 2006:2(4) 465–475
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addition, it would appear that young women with obstructive CAD have a worse
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circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
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month/year of ACE inhibitor, ARB, or DHP initiation, prior 
therapy (β-blocker versus diuretic), and interval between 
baseline BP measurement and the date of ACE inhibitor, 
ARB, or DHP initiation. Additionally, Charlson’s comor-
bidity index, a single score based on the sum of a weighted 
ranking of comorbid conditions, was calculated from patient 
data at baseline in order to compare the overall health status 
of patient groups (Charlson et al 1987). The calculations 
were based on ICD-9 codes, using the methods described 
by Romano et al (1993).
As data were analyzed for patients receiving treatment 
during the period 1998 through 2001, BP goal attainment was 
deﬁ  ned by JNC 6 (Joint National Committee 1997), the JNC 
6 goals were incorporated into the newer JNC 7 guidelines 
after the study period (Chobanian et al 2003). Therefore, JNC 
6/7 BP goal attainment was calculated as the proportion of 
patients with a ﬁ  nal BP reading 140/90 mmHg. Attain-
ment of the American Diabetes Association (ADA) goal for 
hypertension was also calculated, and was deﬁ  ned as the 
proportion of patients with BP 130/80 mmHg (American 
Diabetes Association 2002).
Statistical analyses
To reduce the potential inﬂ  uence of confounding variables, a 
statistical matching technique was utilized. Propensity scores 
(D’Agostino 1998) were calculated as the probability of being 
in the DHP and ACE inhibitor cohorts using a multinomial 
logistic regression model. Patients across the three study 
cohorts (ACE inhibitor, ARB, DHP) were matched using 
propensity scores at a 1:1:1 ratio. A set of three matches was 
identiﬁ  ed as the ﬁ  rst three patients selected in random order 
who matched on the likelihood of being in the DHP and 
ACE inhibitor groups within one-fourth standard deviation 
of the respective propensity scores. This matching process 
continued until there were no more sets of three matching 
patients. One of the advantages of this technique over the 
use of Cox proportional hazard models is that it removes 
differences between the groups where attributes of one treat-
ment group may be completely absent in other treatment 
groups. In retrospective data where treatment assignment is 
very systematic, these differences can impact the regression 
model and cause under/over correction for data within the 
common sample subjects, due to the inﬂ  uence of an unlike 
group in one arm.
The main study outcomes were incremental mean 
change in SBP and DBP from pre- to post-index BP reading 
and the percentage of patients reaching BP goals according 
to JNC 6/7. Categoric variables were presented as the sum 
and percentage of patients, and continuous variables as the 
mean and standard deviation. Baseline characteristics and 
treatment outcomes were compared using a chi-square test 
and analysis of variance (ANOVA) for categorical and 
continuous variables, respectively. Baseline characteris-
tics were tested despite the scoring matching technique 
used, because matching was based on the p-score, and 
not each individual characteristic that was used to gener-
ate the p-score. Therefore, it was still possible that some 
differences could exist between the groups with respect to 
some characteristics. This process also served to test how 
successful the propensity matching had been. No correc-
tions were applied to p-values for multiple comparisons. 
Analyses were performed using SAS version 8.2 (SAS 
Institute, SAS Procedures Guide, Version 8.2, 2002; SAS 
Institute, Cary, NC, USA).
Results
Baseline characteristics
A total of 1875 patients met the original inclusion criteria 
for the study; after applying propensity score matching, a 
total of 660 (220 for each cohort) were included in the ﬁ  nal 
analysis (Table 1). There were no statistically signiﬁ  cant dif-
ferences between the DHP, ACE inhibitor, and ARB groups 
at baseline for mean age, percentage of male patients, and 
pre-index SBP or DBP. Within medication classes, the most 
commonly used agents were: DHP (amlodipine besylate 
[81%]); ACE inhibitor (lisinopril [52%]); ARB (valsartan 
[50%]). The mean intervals between starting and ending 
BP measurements were 256 days (DHP), 261 days (ACE 
inhibitor), and 265 days (ARB). There were no statistically 
signiﬁ  cant differences between the cohorts with respect to 
the measurement intervals.
1998–2001
t −180
days
BP closest to
index date used
for baseline
Last measured
BP used for ending
t + 30
days
Initiation of DHP, ACEI, or ARB
(index date)
t + 360
days
Figure 1 Study time frame. Pre-index BP was deﬁ  ned as the most recent BP reading 
from the date of therapy initiation to 6 months prior to the initiation of therapy. Post-
index BP was deﬁ  ned as the ﬁ  nal BP reading within 30 to 60 days from the index date.
Abbreviations: BP, blood pressure; DHP, dihydropyridine calcium channel blocker; 
ACEI, angiotensin-converting enzyme inhibitor;  ARB, angiotensin receptor blocker.Vascular Health and Risk Management 2006:2(4) 465–475
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Blood pressure outcomes
As shown in Figure 2, mean (SD) SBP reductions in the 
overall sample were –17.5 (21.0) mmHg for patients receiving 
add on DHP therapy, –15.7 (20.2) mmHg for those receiving 
ACE inhibitors as add-on therapy, and –13.0 (21.4) mmHg 
among patients that received add-on treatment with an ARB. 
The reductions in SBP were slightly greater when DHP or 
ACE inhibitors were added on to patients receiving β-blockers 
in comparison to when they were used as additional therapy 
in those receiving diuretics as initial therapy, whereas the 
converse was true for ARBs.
Figure 3 shows that overall mean (SD) reductions in 
DBP in patients who received DHP as add-on therapy 
were –8.8 (12.7) mmHg in comparison with –6.3 (11.4) 
mmHg for those receiving add-on ACE inhibitor therapy, 
and –8.0 (12.2) mmHg in those that received add-on ARBs. 
Reductions in DBP were slightly greater when ACE inhibi-
tors or ARBs were added on to patients receiving initial 
therapy with diuretics versus those receiving β-blockers 
as initial therapy. In contrast to this, reductions in DBP 
with DHP add-on therapy were greater in those on initial 
therapy with β-blockers versus diuretics.
Blood pressure goal attainment is illustrated in Figure 4. 
As shown, 47.3% of study patients in the overall DHP-cohort 
achieved the JNC 6/7 BP goals during the year following 
treatment initiation, in comparison with 40.0% in the ACE 
inhibitor group and 32.2% of those receiving add-on therapy 
with β-blockers. Much of this difference appeared due to 
improved performance among the cohort initially receiving 
β-blockers, for whom goal attainment with the addition of 
DHPs was 52.0% and with the addition of ACE inhibitors it 
was 43.4% versus 30.4% for ARBs.
Discussion
This “real-world” analysis supports the use of combinations 
of antihypertensive drugs in order to reduce SBP and DBP 
and to enable patients to achieve JNC 6/7 BP goals. The addi-
tion of an ACE inhibitor, ARB, or DHP to existing β-blocker 
or diuretic treatment for up to 12 months resulted in signiﬁ  -
cant reductions in SBP and DBP compared with baseline 
values. These results are in agreement with ﬁ  ndings from 
clinical trials showing that more than one antihypertensive 
drug is often required to reduce BP and achieve BP control 
(Hansson et al 1998; ALLHAT Collaborative Research 
Group 2002; Dahlöf et al 2002; Black et al 2003). The 
mean reduction in BP during the study period reported here 
ranged from 13.0 mmHg to 17.5 mmHg for SBP, and from 
6.3 mmHg to 8.8 mmHg for DBP. Sustained BP reductions 
of this magnitude in patients with hypertension are likely to 
represent a clinically meaningful treatment effect (Staessen 
et al 2003; Turnbull et al 2005). 
When comparing the effects of three different antihy-
pertensive drug classes as add-ons to β-blocker or diuretic 
therapy, DHPs were associated with the greatest improve-
ments in BP, followed by ACE inhibitors and then ARBs. 
We observed that SBP was reduced to a statistically greater 
extent by DHPs compared with ARBs. Large-scale clinical 
trials have conﬁ  rmed that DHP-based treatment regimens 
are associated with reduced cardiovascular events compared 
with β-blocker-based therapy (Dahlöf et al 2005) and similar 
reductions to ARB-based antihypertensive regimens (Julius 
et al 2004). The beneﬁ  ts of ACE inhibitor or DHP combi-
nation therapy on SBP is signiﬁ  cant, given the importance 
of SBP as a major risk factor for CVD and the difﬁ  culty of 
Table 1 Propensity score matching – baseline characteristics
Patients (n = 660)  DHP  ACE   ARB
  (n = 220)  (n = 220)  (n = 220)
Mean age (SD)  65.6 (14.8)  65.6 (13.7)  66.1 (14.8)
(years)
Male (%)  66.8  68.6  67.1
Diuretic versus β- 62.7  61.4  60.9
blocker (%)
Charlson Index  0.88 (1.4)  0.83 (1.3)  0.92 (1.5)
Diabetes (%)  45.9  47.7  47.7
CAD (%)  12.2  13.2  11.4
Pre-index SBP mean  156.1 (17.5)  154.9 (16.3)  155.6 (18.4)
(SD) (mmHg)
Pre-index DPB mean  88.5 (11.7)  87.9 (10.7)  88.4 (12.6)
(SD) (mmHg)
Abbreviations: DHP, dihydropyridine calcium channel blocker;  ACE, angiotensin-
converting enzyme inhibitor;  ARB, angiotensin receptor blocker; SD, standard 
deviation; CAD, coronary artery disease; SBP, systolic blood pressure; DBP, 
diastolic blood pressure.
Figure 2 Incremental systolic blood pressure reduction. *p  0.05 versus DHP. 
Abbreviations: DHP, dihydropyridine calcium channel blocker;  ACEI, angioten-
sin-converting enzyme inhibitor;  ARB, angiotensin receptor blocker; BP, blood 
pressure.
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those in men. In addition, pathology and pathophysiology of the disease present significant
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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achieving improvement in this measure (Izzo et al 2000; 
Chobanian et al 2003). When given in combination with 
β-blockers or diuretics, DHPs also resulted in a signiﬁ  cantly 
greater reduction in DBP compared with that achieved with 
ACE inhibitors.
Overall, JNC 6/7 BP goal was achieved by up to 47% of 
patients taking combination therapy in this analysis. How-
ever, a greater proportion of patients attained BP goal when 
either a DHP (47.3%) or an ACE inhibitor (40.0%) was added 
to pre-existing β-blocker or diuretic therapy, compared with 
patients receiving an ARB (32.2%) as add-on therapy. Our 
study used a standard deﬁ  nition of hypertension control based 
on the JNC 6 guidelines, as these were applicable during the 
period for which the data were analyzed (1998 through 2001). 
The recommendations of JNC 6 have been incorporated 
into JNC 7; thus, the outcomes of this study continue to be 
relevant. Nevertheless, 50% of patients in this study had not 
achieved their BP goal with two agents, suggesting that either 
the dose of these agents should have been increased further 
or that additional agents should have been added. Indeed, the 
Irbesartan type II Diabetic Neuropathy Trials showed more 
than three antihypertensive agents were required to control 
BP (Lewis et al 2001).
Although our analysis does not report results for speciﬁ  c 
antihypertensive agents, patient drug therapies were reported. 
The majority of patients taking DHPs (81%) in the study 
received amlodipine besylate, and approximately half the 
patients taking ACE inhibitors and ARBs took lisinopril and 
valsartan, respectively. We recently performed a retrospec-
tive database analysis that speciﬁ  cally assessed the clinical 
effectiveness of amlodipine given as monotherapy or in 
combination with other antihypertensive drugs in reducing 
BP and attaining BP goals (Bisognano et al 2004). There were 
substantial reductions in BP when amlodipine was added to 
antihypertensive regimens. The beneﬁ  ts occurred regardless 
of the number of antihypertensive drugs that patients were 
taking upon initiation of amlodipine (Bisognano et al 2004). 
The observations from the present study corroborate those 
from our earlier study.
The study reported here has some limitations. Firstly, the 
results are based on patient samples from several large US 
general physician practices and may not be generalizable to 
other populations treated by other physicians. Results may 
not be applicable to practices without electronic medical 
records. Secondly, patient adherence to medication regimens 
was not documented. Low rates of adherence or patient 
discontinuation of therapy may affect outcomes with medi-
cations, and the impact of this effect cannot be taken into 
account in this analysis. However, discontinuations and lack 
of adherence are realities of real-world treatment, and while 
they may limit evaluation of pure efﬁ  cacy from the study, 
incorporation of these factors may better reﬂ  ect real-world 
effectiveness. Thirdly, JNC 6 states that if a diuretic is not 
used as the initial antihypertensive it is usually indicated 
as the second agent because its addition will enhance the 
effects of other agents. Therefore, the use of DHPs, ACE 
inhibitors, and ARBs of add-on therapy in patients receiving 
β-blockers as initial therapy suggests poor compliance with 
this recommendation. Fourthly, sample sizes in the present 
study were small and did not allow analysis of results for key 
subpopulations (for example, the elderly and patients with 
diabetes mellitus). The propensity matching technique used 
also reduced the sample size. However, the intent was to 
compare similar cohorts (based on baseline characteristics) 
and this was thought more important than keeping all patients 
Figure 3 Incremental diastolic blood pressure reduction. *p  0.05 versus DHP. 
Abbreviations: DHP, dihydropyridine calcium channel blocker;  ACEI, angioten-
sin-converting enzyme inhibitor;  ARB, angiotensin receptor blocker; BP, blood 
pressure. 
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Figure 4 JNC 6/7 BP goal attainment. *p  0.05 versus DHP. 
Abbreviations: DHP, dihydropyridine calcium channel blocker;  ACEI, angiotensin-
converting enzyme inhibitor;  ARB, angiotensin receptor blocker. 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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in the sample. Finally, the use of a single pre- and post-index 
measurement of BP is a limitation. The single pre- and post- 
index measurement was a prospectively deﬁ  ned end point 
for this analysis based on application of this end point in a 
prior study (Bisognano et al 2004). Alternative deﬁ  nitions 
may provide differing results, however we felt this deﬁ  ni-
tion was the most consistent measure between patients based 
on the structure of the database, and the fairest end point to 
compare across treatment groups.
Another potential limitation of this analysis is that 
channeling bias (Petri and Urquhart 1991) may not be 
fully addressed, although propensity matching analyses 
(D’Agostino 1998) were performed to address between-
group differences in a number of baseline characteristics. 
Channeling bias may occur in observational studies because 
prescribing does not occur by random allocation in clinical 
practice, in contrast to randomized controlled trials where 
treatment assignment is random. As it was not known why 
the prescribing physicians decided upon the use of each anti-
hypertensive agent, whether as initial or subsequent therapy, 
we cannot fully assess whether patient or prescriber factors 
systematically led to different treatment choices for different 
patient types. To the extent that these patient factors were 
collected and incorporated into the propensity score model, 
this effect is largely accounted for. However, these treatment 
choices may have been driven by unobserved factors, such 
as perceptions of or reaction to indications or formulary 
restrictions. However, collecting and correcting for such 
factors were beyond the scope of this study.
Although retrospective cohort analyses such as the study 
reported here have traditionally been considered to have 
limited use in comparing treatments, there is evidence that 
such observational studies and randomized controlled trials 
demonstrate similar treatment effects (Benson and Hartz 
2000; Concato et al 2000). Therefore, despite limitations, 
most of which are inherent in observational studies, this 
report provides important results of treatment outcomes in 
a physician ofﬁ  ce setting. 
In summary, our ﬁ  ndings support the beneﬁ  ts of adding 
a second antihypertensive agent to a patient’s antihyperten-
sive treatment regimen. The greatest beneﬁ  ts are observed 
when DHPs, followed by ACE inhibitors, and then ARBs are 
added as second-line therapy to patients already on β-blocker 
or diuretic therapies. Naturally, if patients have speciﬁ  c 
indications for speciﬁ  c drug treatment (such as proteinuria 
or diabetes), such indications must be followed. These ﬁ  nd-
ings suggest that appropriate and early integration of an 
additional antihypertensive drug into patients’ therapeutic 
regimens, particularly a DHP, together with the appropriate 
dose titration may lead to improved BP outcomes in real- 
world clinical practice.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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